Small scale growth VxP operates with a lean team and offers full development and manufacturing capabilities across small molecules, biologics, and live vaccines, indicating a potential for scalable partnerships and outsourced programs for larger clients seeking flexible collaboration models.

Global regulatory readiness Facilities audited by US-FDA and part of the US Bio-Defense Grid, signaling strong regulatory compliance and capabilities to support regulated development, manufacturing, and public health countermeasures for global pharma partners.

Biologics and vaccines Capabilities span mammalian and microbial biologics, preclinical/toxicology in multiple species including non-human primates, and live virus vaccines, presenting cross-domain opportunities for biopharma clients pursuing complex biologics or vaccine programs.

Regional footprint Operations primarily in the United States with facilities in Europe, India, and East Asia, offering nearshore and offshore engagement options to diversify supply chain, reduce time-to-clinic, and support global clinical development initiatives.

Competitive market positioning While revenue is modest, the combination of regulatory vetting, defense-linked facilities, and end-to-end development and manufacturing services positions VxP as a compelling partner for virtual companies and mid‑sized programs seeking cost‑effective, compliant outsourcing with global reach.